DDInter948 DDInter425
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Cobimetinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib